Vera Therapeutics (VERA) Expected to Announce Earnings on Wednesday

Vera Therapeutics (NASDAQ:VERA) is anticipated to issue its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect Vera Therapeutics to post earnings of ($1.34) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, March 6, 2026 at 12:30 PM ET.

Vera Therapeutics Stock Up 0.7%

Shares of NASDAQ:VERA opened at $42.06 on Tuesday. The stock has a 50-day simple moving average of $46.89 and a 200-day simple moving average of $35.10. The stock has a market capitalization of $2.95 billion, a P/E ratio of -10.54 and a beta of 1.16. Vera Therapeutics has a 1 year low of $18.53 and a 1 year high of $56.05. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.21 and a current ratio of 12.21.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on VERA shares. Bank of America boosted their price objective on shares of Vera Therapeutics from $48.00 to $66.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. JPMorgan Chase & Co. reduced their target price on shares of Vera Therapeutics from $99.00 to $96.00 and set an “overweight” rating on the stock in a report on Friday, December 19th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vera Therapeutics in a report on Wednesday, November 26th. Evercore raised their price objective on Vera Therapeutics from $75.00 to $97.00 and gave the company an “outperform” rating in a research report on Monday, December 8th. Finally, The Goldman Sachs Group upped their target price on Vera Therapeutics from $55.00 to $95.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. Nine analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $77.18.

Insiders Place Their Bets

In other Vera Therapeutics news, Director Patrick G. Enright acquired 5,882 shares of Vera Therapeutics stock in a transaction dated Thursday, December 11th. The stock was acquired at an average cost of $42.50 per share, for a total transaction of $249,985.00. Following the completion of the transaction, the director owned 5,882 shares in the company, valued at approximately $249,985. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 16.30% of the stock is currently owned by insiders.

Institutional Trading of Vera Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new stake in shares of Vera Therapeutics in the 4th quarter valued at $297,000. Invesco Ltd. raised its holdings in Vera Therapeutics by 193.3% during the fourth quarter. Invesco Ltd. now owns 89,851 shares of the company’s stock valued at $4,550,000 after buying an additional 59,219 shares in the last quarter. KVP Capital Advisors LP acquired a new stake in shares of Vera Therapeutics in the fourth quarter worth about $1,656,000. XTX Topco Ltd bought a new stake in shares of Vera Therapeutics during the 4th quarter worth about $508,000. Finally, Virtus Investment Advisers LLC increased its holdings in shares of Vera Therapeutics by 5.7% during the 4th quarter. Virtus Investment Advisers LLC now owns 5,342 shares of the company’s stock valued at $271,000 after acquiring an additional 290 shares during the last quarter. 99.21% of the stock is currently owned by institutional investors and hedge funds.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.